Find and Pitch Jounalists, Get Your Story Covered

Tags: leadership pharma Research & Development research-development biotech

	Profile	Recent Articles on Subject
1	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	Biotechs emerging from stealth take aim at pharma’s prime targets - about 1 month ago As financial headwinds pick up, pharmas are aiming to squeeze more ROI from their R&D - 3 months ago Pharma’s forecast for 2025: Sowing seeds of a rebound - 3 months ago Musk’s rare disease torpedo, hospitals’ pharma fix and other policies leaders are tracking - 3 months ago PharmaVoice’s Crystal Ball: The industry’s AI future - 4 months ago 3 closely watched drugs that failed in the clinic - 4 months ago The big rebrand: Why these 4 biopharmas changed their name this year - 5 months ago Pharma takes aim at a wily foe — the Epstein-Barr virus - 6 months ago 2024 PharmaVoice 100s: Rare Disease Warriors - 6 months ago 2024 PharmaVoice 100s: Trailblazers - 6 months ago California is a life sciences leader. Joe Panetta has been one of its most vocal advocates. - 7 months ago Who’s winning in biotech’s tight market? - 7 months ago Pharma’s ‘it’ therapy — a new drug class gaining steam - 8 months ago Up-and-comers look for an edge in the bustling ADC field - 10 months ago Pharma’s R&D gamble: picking pipeline winners in a risky field - 11 months ago Where competition is heating up in pharma - 11 months ago The biggest questions hanging over pharma in 2024 - about 1 year ago PharmaVoice’s Crystal Ball: What’s next in drug innovation and clinical trials - over 1 year ago Does BioMarin’s CEO shuffle signal bigger changes ahead? - over 1 year ago PharmaVoice 100s: Entrepreneurs - over 1 year ago
2	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	How the race for the next obesity drug is shaping up - about 2 months ago Merck is a new year outlier with its diabetes drug - 4 months ago Is pharma still fearful of the Inflation Reduction Act? - 8 months ago STAT+: More tumult at BIO amid the company’s fourth CEO in four years - 11 months ago Novartis is building a new radioligand plant in China - over 1 year ago
3	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: A reporter’s JPM notebook: a look ahead for biopharma VC investing - 3 months ago STAT+: Biotech FogPharma raises $145 million in anticipation of more clinical trials, pharma partnerships - about 1 year ago
4	Michael Gibney Pharma Voice Teacher of English. Teacher of politics. Santiago, Chile educationpolitics	By the numbers: J&J, GSK lead J.P. Morgan deal announcements in 2025, the largest turnout in years - 3 months ago Will 2025 mark pharma’s pivot to bigger deals after years of lackluster M&A? - 3 months ago Among 2024’s modest M&A action, cancer, immunology and neuroscience deals trickle in - 6 months ago Two former Alexion leaders fight through layoffs and a tough market to maintain a rare disease biotech - 6 months ago Big Pharma earnings hang hope on the next generation of blockbusters - 6 months ago 2024 PharmaVoice 100s: Cell and Gene Therapy Pioneers - 6 months ago 2024 PharmaVoice 100s: Biotech Pathfinders - 6 months ago As new Alzheimer’s biomarkers come into play, here’s where the money is going - 6 months ago Top pharma and biotech conferences 2025 - 7 months ago A biotech dousing ‘fires’ in the brain that plagued a bestselling author - 9 months ago A new biotech tackling IBD joins a race against Lilly and Gilead for a promising pill - 9 months ago Has pharma emerged from the ‘age of uncertainty’? - 9 months ago Don’t call it a comeback: Biotech’s CNS resurgence forges Big Pharma connections - 10 months ago 3 up-and-coming US biotech hotspots - 11 months ago How pharma’s surging M&A is impacting the industry’s tech sector - about 1 year ago Biosimilar uptake appears to finally be on the upswing, and Biocon Biologics is betting on the sector’s future - about 1 year ago How to make 2024 a banner year for biopharma, despite the headwinds - over 1 year ago Pharma’s financial market will be a tale of two cities in 2024 - over 1 year ago Biopharma’s FTC headache deepens with guideline shifts years in the making - over 1 year ago Real Chemistry’s CEO on biopharma’s outlook in 2024 - over 1 year ago A biotech tackles drug discovery with transcription factor know-how - over 1 year ago The thorniest questions facing pharma, according to a leading bioethicist - over 1 year ago The PharmaVoice 100: Rare disease warriors - over 1 year ago
5	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	Biopharma in 2025: Outlook for Obesity Meds, Drug Prices, Regulation & More - 4 months ago 3 Biotech IPOs, $703M Raised for Clinical Trials in Cancer, Immunology & Endocrine Disorders - 7 months ago
6	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	East Asians under-represented in biopharma leadership - 4 months ago BioMarin’s big day today - 8 months ago
7	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	Milk-based therapies could be coming. This biotech CEO is aiming to lead the way. - 5 months ago Can BioNTech sustain a post-COVID mRNA pipeline? Oncology is the next hope. - 8 months ago In a Duchenne market beset by problems, Capricor data marks a bright spot - 9 months ago Behind the powerful computations, AI’s role in pharma is still beset by challenges - 11 months ago 4 offbeat biotechs making a splash in the life sciences - 12 months ago These biotech hotspots are ripe for IPOs - about 1 year ago
8	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: We’re reading about GSK leaving BIO, an AbbVie schizophrenia drug failing, and more - 5 months ago STAT+: Pharmalittle: We’re reading about biotech startups, Pfizer’s RSV vaccine, and more - about 1 year ago STAT+: Pharmalittle: We’re reading about Biocon eyeing weight loss drugs, Sanofi layoffs, and more - about 1 year ago STAT+: Pharmalittle: We’re reading about Boehringer biosimilar frustrations, FTC warnings, and more - about 1 year ago STAT+: Pharmalittle: We’re reading about BIO cutting ties with WuXi, EU pharma rules, and more - about 1 year ago STAT+: Pharmalittle: We’re reading about Lilly selling drugs directly, UCB leaving BIO, and more news - over 1 year ago STAT+: Pharmalittle: Pfizer is leaving the BIO trade group; CVS drug-pricing plan may not lower costs for consumers - over 1 year ago STAT+: Pharmalittle: Bioscience job market is upside down; Sanofi and Regeneron’s blockbuster Dupixent may find bigger market - over 1 year ago STAT+: Pharmalittle: Pharma moves closer to a pricing deal with U.K.; FDA to review AstraZeneca request for self-administered flu vax - over 1 year ago STAT+: Pharmalittle: Life sciences deals on track to hit lowest point since 2017; EU regulators order Illumina to divest Grail - over 1 year ago
9	Lizzy Lawrence STAT News Medical devices reporter at STATnews. Loves news tips. medical reportingnews	STAT+: Pharma giant GSK is quitting BIO in latest setback for the lobbying group - 6 months ago
10	Sarah Owermohle STAT News Health reporter @STATNews. Covers Biden's agenda. Washington, District of Columbia health policyjournalism	STAT+: Pharma giant GSK is quitting BIO in latest setback for the lobbying group - 6 months ago

Journalists covering biopharma